Summary:
- The article examines the clinical impact of GLP-1 receptor agonists (such as semaglutide and tirzepatide) in the evolving landscape of obesity management.
- It highlights ongoing medical research and clinician concerns regarding long-term efficacy, potential side effects, and the necessity for comprehensive, evidence-based treatment protocols.